Format

Send to

Choose Destination
Eur Heart J. 2019 Jun 7;40(22):1764-1770. doi: 10.1093/eurheartj/ehx811.

Cancer therapy-induced cardiomyopathy: can human induced pluripotent stem cell modelling help prevent it?

Stack JP1,2,3,4, Moslehi J5,6, Sayed N1,2,3, Wu JC1,2,3.

Author information

1
Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.
2
The Institute for Stem Cell Biology and Regenerative Medicine, 265 Campus Drive, 3rd Floor, Stanford, CA, USA.
3
Division of Cardiology, Department of Medicine, Stanford University School of Medicine, 300 Pasteur Drive S102, Stanford, CA, USA.
4
Department of Comparative Medicine, Stanford University School of Medicine, 300 Pasteur Drive, Edwards, Stanford, CA, USA.
5
Division of Cardiology, Department of Medicine, Vanderbilt School of Medicine, 2220 Pierce Avenue, 383 Preston Research Building, Nashville, TN USA.
6
Cardio-Oncology Program, Vanderbilt School of Medicine, 2220 Pierce Avenue, 383 Preston Research Building, Nashville, TN, USA.

Abstract

Cardiotoxic effects from cancer therapy are a major cause of morbidity during cancer treatment. Unexpected toxicity can occur during treatment and/or after completion of therapy, into the time of cancer survivorship. While older drugs such as anthracyclines have well-known cardiotoxic effects, newer drugs such as tyrosine kinase inhibitors, proteasome inhibitors, and immunotherapies also can cause diverse cardiovascular and metabolic complications. Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are increasingly being used as instruments for disease modelling, drug discovery, and mechanistic toxicity studies. Promising results with hiPSC-CM chemotherapy studies are raising hopes for improving cancer therapies through personalized medicine and safer drug development. Here, we review the cardiotoxicity profiles of common chemotherapeutic agents as well as efforts to model them in vitro using hiPSC-CMs.

KEYWORDS:

Cardio-oncology ; Chemotherapy ; Genomics ; Induced pluripotent stem cells ; Precision medicine

PMID:
29377985
PMCID:
PMC6554650
[Available on 2020-06-07]
DOI:
10.1093/eurheartj/ehx811

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center